Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, including infections caused by resistant bacteria and other pathogens. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-295-0928orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news